Editas Medicine, Inc. (EDIT): Price and Financial Metrics
GET POWR RATINGS... FREE!
EDIT POWR Grades
- Value is the dimension where EDIT ranks best; there it ranks ahead of 46.39% of US stocks.
- EDIT's strongest trending metric is Growth; it's been moving up over the last 168 days.
- EDIT ranks lowest in Sentiment; there it ranks in the 2nd percentile.
EDIT Stock Summary
- EDIT's price/sales ratio is 49.73; that's higher than the P/S ratio of 96.13% of US stocks.
- Revenue growth over the past 12 months for Editas Medicine Inc comes in at -73.26%, a number that bests only 2.27% of the US stocks we're tracking.
- The volatility of Editas Medicine Inc's share price is greater than that of 92.13% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Editas Medicine Inc, a group of peers worth examining would be MORF, XBIT, CYCN, EVGN, and NKTR.
- Visit EDIT's SEC page to see the company's official filings. To visit the company's web site, go to www.editasmedicine.com.
EDIT Valuation Summary
- EDIT's price/sales ratio is 53.5; this is 1307.89% higher than that of the median Healthcare stock.
- EDIT's price/earnings ratio has moved down 17.1 over the prior 68 months.
- EDIT's price/earnings ratio has moved down 17.1 over the prior 68 months.
Below are key valuation metrics over time for EDIT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| EDIT | 2021-08-31 | 53.5 | 7.1 | -26.0 | -24.1 |
| EDIT | 2021-08-30 | 52.0 | 6.9 | -25.3 | -23.4 |
| EDIT | 2021-08-27 | 55.1 | 7.3 | -26.8 | -24.9 |
| EDIT | 2021-08-26 | 53.7 | 7.1 | -26.2 | -24.2 |
| EDIT | 2021-08-25 | 55.2 | 7.3 | -26.9 | -24.9 |
| EDIT | 2021-08-24 | 54.4 | 7.2 | -26.5 | -24.6 |
EDIT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- EDIT has a Quality Grade of D, ranking ahead of 12.21% of graded US stocks.
- EDIT's asset turnover comes in at 0.12 -- ranking 248th of 682 Pharmaceutical Products stocks.
- SMMT, SAGE, and VSTM are the stocks whose asset turnover ratios are most correlated with EDIT.
The table below shows EDIT's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.120 | 1 | -0.458 |
| 2021-03-31 | 0.140 | 1 | -0.450 |
| 2020-12-31 | 0.158 | 1 | -0.468 |
| 2020-09-30 | 0.164 | 1 | -0.447 |
| 2020-06-30 | 0.065 | 1 | -0.704 |
| 2020-03-31 | 0.057 | 1 | -0.806 |
EDIT Price Target
For more insight on analysts targets of EDIT, see our EDIT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $50.75 | Average Broker Recommendation | 1.79 (Moderate Buy) |
EDIT Stock Price Chart Interactive Chart >
EDIT Price/Volume Stats
| Current price | $17.42 | 52-week high | $73.03 |
| Prev. close | $17.81 | 52-week low | $16.37 |
| Day low | $17.35 | Volume | 3,040,011 |
| Day high | $19.09 | Avg. volume | 2,166,784 |
| 50-day MA | $27.60 | Dividend yield | N/A |
| 200-day MA | $40.30 | Market Cap | 1.19B |
Editas Medicine, Inc. (EDIT) Company Bio
Editas Medicine Inc. operates as a genome editing company. It focuses on translating its genome editing technology into a class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a range of diseases at the genetic level. Editas Medicine Inc. was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. The company was founded in 2013 and is based in Cambridge, Massachusetts.
Latest EDIT News From Around the Web
Below are the latest news stories about Editas Medicine Inc that investors may wish to consider to help them evaluate EDIT as an investment opportunity.
DDD Partners, LLC Buys Intel Corp, Novo Nordisk A/S, Broadcom Inc, Sells Adaptive ...Investment company DDD Partners, LLC (Current Portfolio) buys Intel Corp, Novo Nordisk A/S, Broadcom Inc, DocuSign Inc, Atlas Corp, sells Adaptive Biotechnologies Corp, Editas Medicine Inc, Magna International Inc, Activision Blizzard Inc, Gentex Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, DDD Partners, LLC. |
Editas (EDIT) Focuses on Developing Gene-Editing Eye DrugEditas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe. |
Here is What Hedge Funds Think About Editas Medicine, Inc. (EDIT)The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September 30th. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […] |
What Kind Of Investors Own Most Of Editas Medicine, Inc. (NASDAQ:EDIT)?If you want to know who really controls Editas Medicine, Inc. ( NASDAQ:EDIT ), then you'll have to look at the makeup... |
Why Editas Medicine Stock Is Tumbling This WeekShares of Editas Medicine (NASDAQ: EDIT) were tumbling 13% lower this week as of the market close on Thursday, based on data from S&P Global Market Intelligence. Editas Medicine CEO James Mullen specifically mentioned base editing in his comments at the J. P. Morgan conference and seemed a bit defensive. |
EDIT Price Returns
| 1-mo | -37.56% |
| 3-mo | -52.56% |
| 6-mo | -58.39% |
| 1-year | -71.21% |
| 3-year | -15.68% |
| 5-year | -4.91% |
| YTD | -34.39% |
| 2021 | -62.13% |
| 2020 | 136.78% |
| 2019 | 30.15% |
| 2018 | -25.97% |
| 2017 | 89.34% |
Continue Researching EDIT
Want to do more research on Editas Medicine Inc's stock and its price? Try the links below:Editas Medicine Inc (EDIT) Stock Price | Nasdaq
Editas Medicine Inc (EDIT) Stock Quote, History and News - Yahoo Finance
Editas Medicine Inc (EDIT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...